Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Imfinzi is a prescription programmed death-ligand 1 blocking antibody containing durvalumab. Current U.S. labeling includes several lung cancers, biliary tract cancer, unresectable hepatocellular carcinoma, selected endometrial cancer, bladder cancer, and resectable gastric or gastroesophageal junction adenocarcinoma.
read more about imfinzi ...Durvalumab binds to PD-L1 and blocks its interaction with PD-1 and CD80. This removes inhibitory signaling that suppresses T-cell activity and increases immune activity against susceptible tumor cells.
Imfinzi is used in adults under indication-specific criteria for resectable, unresectable, or metastatic non-small cell lung cancer, limited-stage or extensive-stage small cell lung cancer, locally advanced or metastatic biliary tract cancer, unresectable hepatocellular carcinoma, dMMR advanced or recurrent endometrial cancer, high-risk non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, and resectable gastric or gastroesophageal junction adenocarcinoma.
Imfinzi is administered by intravenous infusion over 60 minutes. Dose and schedule depend on the cancer, body weight, and accompanying medicines. Current adult regimens include 1500 mg every three or four weeks in selected settings and 1120 mg every three weeks during carboplatin and paclitaxel treatment for dMMR endometrial cancer.
Imfinzi can cause immune-mediated pneumonitis, colitis, hepatitis, endocrine disorders, nephritis, and severe skin reactions. Other serious concerns include infusion reactions, complications after stem cell transplantation, and fetal harm. Treatment can require interruption or permanent discontinuation based on toxicity severity.
Imfinzi is a PD-L1 blocking monoclonal antibody containing durvalumab.
Imfinzi is given as an intravenous infusion over 60 minutes.
Yes. Current labeling includes several non-small cell and small cell lung cancer settings.
Yes. Immune-mediated reactions can affect the lungs, intestines, liver, endocrine glands, kidneys, skin, and other organs.
DailyMed - IMFINZI - durvalumab injection. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=Durvalumab. Date Accessed October 2, 2026.
Durvalumab Injection - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a617030.html. Date Accessed October 2, 2026.
Durvalumab - National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/durvalumab. Date Accessed October 2, 2026.
Search Orphan Drug Designations and Approvals - Durvalumab for Gastric Cancer Including Gastroesophageal Junction Cancer. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=965823. Date Accessed October 2, 2026.
Search Orphan Drug Designations and Approvals - Durvalumab for Small Cell Lung Cancer. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=691319. Date Accessed October 2, 2026.